PROSTVAC®-VF Phase II Study Overview
Study Overview
Therion is conducting a Phase II randomized, double blind, controlled study to evaluate the safety and efficacy of PROSTVAC®-VF in combination with GM-CSF in patients with androgen-independent adenocarcinoma of the prostate.
Study Endpoints
The primary endpoint for Therion's PROSTVAC-VF Phase II Study is progression-free survival defined as the proportion of patients who remain alive and progression-free at the end of the study.
Secondary and exploratory study endpoints include:
Safety
Time to progression
Time to onset of tumor-associated pain
Effect of vaccination on PSA levels
Immune response to vaccination
Site Locations
Click here for a list of study sites
|
